The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


Objectives: To isolate Azadirachtin-A, from Seeds of Azadirachta indica and to perform molecular docking studies for antiproliferative activity against cervical cancer. Methods: The Current studies on Azadirachtin-A, a potent cervical anticancer agent, was designed for the isolation of Azadirachtin-A, from neem fruits collected from local area (Ibrahimpatnam), the seeds were first separated, dried and made in to coarse powder. The seed kernels was defatted and extracted with methanol using soxhlet apparatus. Methanolic extract of seeds were subjected to direct reverse phase High Performance Liquid Chromatography (HPLC) for separation of Azadirachtin-A, by molecular docking of Azadirachtin-A, using Molecular Operating Environment (MOE) 2008 software Findings: This revealed that Azadirachtin-A, has an affinity of 59.2% and 72% towards amino acids like Glycine 131 and Lysine 89 with polar intractions. Azadirachtin-A, found to interact with Cyclin E, was retrieved from the Protein Data Bank (PDB code: 1W98). The Azadirachtin-A, showed excellent, Increase Life Span (63.44 and 82.56), reduced the viable cells (30.4 ± 1.5 and 24.5 ± 1.6), and tumor volume (1.2 ± 0.05 and 1.0 ± 0.05) when compared to standard drug 5-Fluorouracil. Application: Azadirachtin-A, showed significant docking interaction with Cyclin E, active site using windows 2002, MOE 2008 software. Result showed that Azadirachtin-A, may lead to potent cervical anticancer agent.

Keywords

Azadirachtin-A, Azadirachta indica, Cervical Cancer, 5-Fluorouracil, (HeLa) Henrietta Lacks Cell Line, Molecular Docking.
User